Lupus kliniske forsøg i Texas
26 studier for Lupus søger deltagere på steder i Texas.
Byer i Texas
- Houston13 studier
- Dallas6 studier
- Allen4 studier
- Arlington4 studier
- Frisco4 studier
- Mesquite4 studier
- El Paso4 studier
- San Antonio4 studier
Officiel studietekst (engelsk)
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Sl0044 50738, Bellaire
- Sl0044 50781, El Paso
- Sl0044 50673, Fort Worth
- og 6 flere
RekruttererFase 3
Alder 16 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06617325Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
- Prolato Clinical Research Center, Houston
RekruttererFase 2
Alder 18 til 100 · Alle køn · Opdateret 1. okt. 2026 · NCT05268289A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
- Amarillo Center for Clinical Research, Amarillo
- Precision Comprehensive Clinical Research Solutions - Colleyville, Colleyville
- Precision Comprehensive Clinical Research Solutions, Euless
- og 4 flere
RekruttererFase 2
Alder 18 til 74 · Alle køn · Opdateret 1. okt. 2026 · NCT07409181Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- Novel Research LLC, Bellaire
- Accurate Clinical Research, League City
- Epic Medical Research, Red Oak
RekruttererFase 3
Alder 12 til 100 · Alle køn · Opdateret 1. okt. 2026 · NCT06133972An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Research Site, El Paso
- Research Site, Houston
RekruttererFase 3
Alder 5 til 17 · Alle køn · Opdateret 30. sep. 2026 · NCT05835310A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Research Site, Austin
- Research Site, Baytown
- Research Site, Colleyville
- og 3 flere
RekruttererFase 3
Alder 18 til 70 · Alle køn · Opdateret 25. sep. 2026 · NCT07430306A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Amarillo Medical Specialists Rheumatology, Amarillo
- Amarillo Center for Clinical Research, Amarillo
- Arthritis and Rheumatology Research Institute, Frisco
- og 5 flere
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 25. sep. 2026 · NCT07438496A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
- Epic Medical Research /ID# 279180, Red Oak
RekruttererFase 1
Alder 18 til 75 · Alle køn · Opdateret 25. sep. 2026 · NCT07607964Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
- og 2 flere
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT03816345Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
- Research Site, Allen
- Research Site, Mesquite
RekruttererFase 1
Alder 18 til 65 · Alle køn · Opdateret 18. sep. 2026 · NCT07201558Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
- Baylor College of Medicine, Houston
RekruttererFase 1
Alder 18 til 60 · Alle køn · Opdateret 14. sep. 2026 · NCT06975787A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
- North Texas Center for Clinical Research, Frisco
- Accurate Clinical Research, Humble
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 14. sep. 2026 · NCT07355218A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
- The University of Texas Southwestern Medical Center, Dallas
RekruttererFase 2
Alder 12 til 70 · Alle køn · Opdateret 14. sep. 2026 · NCT07570862A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
- Allen Arthritis, Allen
- Arthritis and Rheumatology Research Institute PLLC, Allen
- Arthritis Care of Texas, Corpus Christi
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 11. sep. 2026 · NCT07332481A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- Arthritis Care of Texas - Corpus Christi, Corpus Christi
- Lone Star Arthritis & Rheumatology Associates, P.C., Denton
- El Paso Medical Research Institute (MedResearch, Inc), El Paso
- og 1 flere
RekruttererObservationsstudie
Alder 16 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT07175285RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- University of Texas MD Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 18 til 65 · Alle køn · Opdateret 26. aug. 2026 · NCT06121297Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
- Texas Transplant Institute, San Antonio
RekruttererFase 2
Alder 12 til 65 · Alle køn · Opdateret 24. aug. 2026 · NCT07053800A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
- Integrative Rheumatology of South Texas - Harlingen /ID# 276458, Harlingen
RekruttererFase 1
Alder 18 til 75 · Alle køn · Opdateret 10. aug. 2026 · NCT06977724A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
- Rheumatology Care Center, PLLC, Bellaire
- Texas Arthritis Center, El Paso
- Novel Research, LLC., Houston
- og 3 flere
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 30. jul. 2026 · NCT07201129A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
- Investigative Site, Allen
- Investigative Site, Arlington
- Investigative Site, Colleyville
RekruttererFase 2
Alder 18 til 80 · Alle køn · Opdateret 27. jul. 2026 · NCT07260877A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
- Stryde Research, Plano
- Tranquil Clinical Research, Webster
RekruttererFase 1
Alder 18 til 70 · Alle køn · Opdateret 5. jun. 2026 · NCT06613360A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants
- US04-0, Irving
- US02-0, San Antonio
RekruttererFase 1/2Frivillige med god helbredstilstand velkomne
Alder 18 til 70 · Alle køn · Opdateret 2. jun. 2026 · NCT06625671Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
- M D Anderson Cancer Center, Houston
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 20. maj 2026 · NCT04751396Lupus Landmark Study: A Prospective Registry and Biorepository
- UT Southwestern Medical Center, Dallas
RekruttererObservationsstudie
Alder 18 til 110 · Alle køn · Opdateret 15. apr. 2026 · NCT05934149Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
- MD Anderson Cancer Center, Houston
- The University of Texas Health Science Center at Houston, Houston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 15. apr. 2026 · NCT06434363A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
- Climb Bio Investigative Site #100104, Allen
- Climb Bio Investigative Site #100101, San Antonio
RekruttererFase 1
Alder 18 til 65 · Alle køn · Opdateret 27. mar. 2026 · NCT07011043Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.